{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\n In study"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": ", researchers profiled 84 long non‐coding RNAs in plasma samples from breast cancer patients and healthy individuals. Among the transcripts examined, A2ML1‐AS1—together with GAS5 and SNHG5—was one of only three lncRNAs consistently detected in all samples. This uniform detection across both patient and control groups indicates that A2ML1‐AS1 is stably present in plasma. However, its similar expression levels in both cohorts suggest that while A2ML1‐AS1 may reflect a baseline circulating lncRNA profile, it does not serve as a differential diagnostic marker for breast cancer using the current plasma analysis technique."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": "\n "}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "M Sterbova, E Pazourkova, S Santorova-Pospisilova, et al. "}, {"type": "b", "children": [{"type": "t", "text": "The use of Human Inflammatory Response and Autoimmunity RT2 lncRNA PCR Array for plasma examination in breast cancer patients prior to therapy."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Neoplasma (2019)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.4149/neo_2018_180907N679"}], "href": "https://doi.org/10.4149/neo_2018_180907N679"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "30943749"}], "href": "https://pubmed.ncbi.nlm.nih.gov/30943749"}]}]}]}